Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis



This meta-analysis was designed to compare the effectiveness of the combination of transarterial chemoembolization (TACE) and percutaneous radiofrequency ablation (PRFA) with that of TACE and PRFA monotherapy in hepatocellular carcinoma (HCC).


Randomized controlled trials were searched using various databases, and six studies were revealed on comparing TACE plus PRFA with TACE and/or PRFA alone for the treatment for HCC. Overall survival rate and recurrence-free survival rate were analyzed and compared. All statistic analyses were conducted using Review Manager (version 4.2.2.) from the Cochrane collaboration.


Meta-analysis data revealed that TACE plus PRFA had significantly better effectiveness on 1- and 3-year overall survival rate(odds ratio [OR] 1-year = 4.61, 95 % confidence interval [95 % CI] 2.26–9.42, P < 0.0001; OR 3-year = 2.79, 95 % CI 1.69–4.61, P < 0.0001) and 3-year recurrence-free survival rate ([OR] 3-year = 3.00, [95 % CI] 1.75–5.13, P < 0.0001) than that of TACE and/or PRFA alone treatment. There was no significant difference between the combined therapy and monotherapy on 1-year recurrence-free survival rate ([OR] 1-year = 1.55, [95 % CI] 0.91–2.65, P = 0.11).


The data of our study indicate that the combination of TACE and PRFA has better effectiveness than that of TACE and PRFA monotherapy in the treatment for patients with HCC.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2


  1. Bruix J, Sherman M (2005) Practice guidelines committee, American association for the study of liver diseases management of hepatocellular carcinoma. Hepatology 42:1208–1236

  2. Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127:S179–S185

  3. Buscarini L, Buscarini E, Di Stasi M et al (1999) Percutaneous radiofrequency thermal ablation combined with transcatheter arterial chemoembolization in the treatment of large hepatocellular carcinoma. Ultraschall Med 20:47–53

  4. Chen MS, Li JQ, Zheng Y et al (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocelluar carcinoma. Ann Surg 243:321–328

  5. Cho YK, Kim JK, Kim MY et al (2009) Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49:453–459

  6. Egger M, Smith GD, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

  7. Ferenci P, Fried M, Labrecque D et al (2010) Hepatocellular carcinoma(HCC): a global perspective. J Clin Gastroenterol 44:239–245

  8. Germani G, Pleguezuelo M, Gurusamy K et al (2010) Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 52:380–388

  9. Higgins JP, Altman DG, Gotzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928

  10. Jarnagin W, Chapman WC, Curley S et al (2010) Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxf) 12:302–310

  11. Kim KM, Kim JH, Park IS et al (2009) Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 24:806–814

  12. Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, Sung KB, Kim PN (2012) Hepatocellular carcinomas 2–3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol 81:e189–e193

  13. Li ZR, Kang Z, Qian JS, Zhu KS, Jiang ZB, Huang MS, Guan SH, Shan H (2007) Radiofrequency ablation with or without transcather arterial chemoembolization for management of hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 27:1749–1751

  14. Livraghi T, Goldberg SN, Lazzaroni S et al (2000) Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology 214:761–768

  15. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442

  16. Marelli L, Shusang V, Buscombe JR et al (2009) Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unrescetable hepatocellular cancer. J Nucl Med 50:871–877

  17. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K (2010) Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 116:5452–5460

  18. Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: globocan 2000. Int J Cancer 94:153–156

  19. Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen MS (2012) Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 262:689–700

  20. Poon RT, Ngan H, Lo CM, Liu CL, Fan ST, Wong J (2000) Transarterial chemoembolization for inoperable hepatocellular carcinoma and post resection intrahepatic recurrence. J Oncol Surg 73:109–114

  21. Shen SQ, Xiang JJ, Xiong CL, Wu SM, Zhu SS (2005) Intraoperative radiofrequency thermal ablation combined with portal vein infusion chemotherapy and transarterial chemoembolization for unresectable HCC. Hepatogastroenterology 52:1403–1407

  22. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K (2009) Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 252:905–913

  23. Tateishi R, Shiina S, Teratani T et al (2005) Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1000 cases. Cancer 103:1201–1209

  24. Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS (2005) Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation. Ai Zheng 24:827–833

  25. Wang W, Shi J, Xie WF et al (2010) Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int 30:741–749

  26. Wang N, Guan Q, Wang K et al (2011) TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis. Med Oncol 28:1038–1043

  27. Xu L, Li P, Chen MS, Pang XH, Gao HJ, Peng ZW, Liang HH, Zhang YJ, Li JQ (2008) Percutaneous radiofrequency ablation combined with other minimally invasive treatments for recurrent hepatocellular carcinoma after hepatectomy. Zhonghua Wai Ke Za Zhi 46:1617–1620

  28. Yang JD, Roberts LR (2010) Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7:448–458

  29. Yang P, Liang M, Zhang Y, Shen B (2008) Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv Ther 25:787–794

  30. Yang W, Chen MH, Wang MQ, Cui M, Gao W, Wu W, Wu JY, Dai Y, Yan K (2009) Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res 39:231–240

  31. Yuen MF, Chan AO, Wong BC et al (2003) Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol 98:1181–1185

  32. Zhang Z, Wu M, Chen H, Chen D, He J (2002) Percutaneous radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi 40:826–829

  33. Zhao M, Wang JP, Li W, Huang ZL, Zhang FJ, Fan WJ, Zhang L, Li XS, Pan CC, Wu PH (2011) Comparison of safety and efficacy for transcatheter arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors. Zhonghua Yi Xue Za Zhi 91:1167–1172

Download references

Conflict of interest

We declare that we have no conflict of interest.

Author information

Correspondence to Lin-feng Xu.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ni, J., Liu, S., Xu, L. et al. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 139, 653–659 (2013).

Download citation


  • Transarterial chemoembolization
  • Percutaneous radiofrequency ablation
  • Hepatocellular carcinoma
  • Meta-analysis